Volume 12, Issue 12, Pages (November 2011)

Slides:

Advertisements

Similar presentations

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast.

Advertisements

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Fever of unknown origin and cancer: a population-based study

Volume 14, Issue 12, Pages (November 2013)

Volume 14, Issue 4, Pages (April 2013)

Ki67 in breast cancer: prognostic and predictive potential

Volume 12, Issue 9, Pages (September 2011)

Chee-Seng Tan, MRCP, David Gilligan, FRCPE, Dr Simon Pacey, FRCP

Volume 6, Issue 7, Pages (July 2005)

Volume 8, Issue 12, Pages (December 2007)

Volume 18, Issue 6, Pages (June 2017)

Pharmacogenetics and future drug development and delivery

Volume 349, Issue 9057, Pages (April 1997)

Volume 12, Issue 11, Pages (October 2011)

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Volume 18, Issue 7, Pages (July 2017)

Volume 9, Issue 4, Pages (April 2008)

Volume 19, Issue 2, Pages (February 2018)

Tinnitus Dr David Baguley, PhD, Don McFerran, FRCS, Prof Deborah Hall, PhD The Lancet Volume 382, Issue 9904, Pages (November 2013) DOI: /S (13)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 13, Issue 12, Pages (December 2012)

Volume 9, Issue 12, Pages (December 2008)

Volume 9, Issue 5, Pages (May 2008)

Volume 14, Issue 3, Pages (March 2013)

Volume 366, Issue 9499, Pages (November 2005)

Aspirin in the prevention of cancer – Author's reply

Volume 374, Issue 9707, Pages (December 2009)

Volume 9, Issue 9, Pages (September 2008)

Volume 10, Issue 6, Pages (June 2009)

Volume 373, Issue 9663, Pages (February 2009)

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Volume 14, Issue 7, Pages (June 2013)

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Volume 366, Issue 9484, Pages (August 2005)

Adjuvant chemotherapy for rectal cancer – Authors' reply

Volume 18, Issue 7, Pages (July 2017)

Volume 16, Issue 6, Pages (June 2015)

Volume 9, Issue 4, Pages (April 2008)

Psychological response and survival in breast cancer

Volume 13, Issue 12, Pages (December 2012)

Cold water immersion: sudden death and prolonged survival

Volume 6, Issue 6, Pages (June 2005)

Volume 11, Issue 4, Pages (April 2010)

Volume 9, Issue 9, Pages (September 2008)

Volume 14, Issue 11, Pages (October 2013)

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Volume 373, Issue 9666, Pages (March 2009)

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Confessions of a journal junkie

Volume 373, Issue 9676, Pages (May 2009)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Volume 11, Issue 3, Pages (March 2010)

Volume 5, Issue 4, Pages (April 2018)

Volume 16, Issue 8, Pages (August 2015)

Volume 373, Issue 9668, Pages (March 2009)

Volume 19, Issue 2, Pages (February 2018)

Volume 373, Issue 9668, Pages (March 2009)

A Translational View of the Molecular Pathogenesis of Lung Cancer

Volume 11, Issue 1, Pages (January 2010)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 13, Issue 5, Pages (May 2012)

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

A disease of the osteoblast

Presentation transcript:

Volume 12, Issue 12, Pages 1134-1142 (November 2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data Dr Angelo Di Leo, MD, Christine Desmedt, PhD, Prof John M S Bartlett, MD, Fanny Piette, PhD, Bent Ejlertsen, MD, Prof Kathleen I Pritchard, MD, Denis Larsimont, MD, Prof Christopher Poole, MD, Prof Jorma Isola, MD, Prof Helena Earl, MD, Henning Mouridsen, MD, Frances P O'Malley, MD, Fatima Cardoso, MD, Minna Tanner, MD, Alison Munro, PhD, Prof Chris J Twelves, MD, Christos Sotiriou, MD, Lois Shepherd, MD, Prof David Cameron, MD, Prof Martine J Piccart, MD, Marc Buyse, PhD The Lancet Oncology Volume 12, Issue 12, Pages 1134-1142 (November 2011) DOI: 10.1016/S1470-2045(11)70231-5 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Interaction between gene status and treatment effect, by survival analysis Survival by (A) HER2 status and (B) TOP2A status. CMF=cyclophosphamide, methotrexate, and fluorouracil. o=observed events. The Lancet Oncology 2011 12, 1134-1142DOI: (10.1016/S1470-2045(11)70231-5) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Event-free survival and overall survival, by gene status Survival by (A) HER2 status (B) TOP2A status. CMF=cyclophosphamide, methotrexate, and fluorouracil. The Lancet Oncology 2011 12, 1134-1142DOI: (10.1016/S1470-2045(11)70231-5) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Interaction between molecular subgroup and treatment effect (event-free survival analysis) CMF=cyclophosphamide, methotrexate, and fluorouracil. o=observed events. The Lancet Oncology 2011 12, 1134-1142DOI: (10.1016/S1470-2045(11)70231-5) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 4 Event-free survival analysis, by molecular subgroups Survival in patients with (A) highly hormone-sensitive tumours, (B) moderately hormone-sensitive tumours, (C) HER2-amplified tumours, and (D) triple-negative tumours. The Lancet Oncology 2011 12, 1134-1142DOI: (10.1016/S1470-2045(11)70231-5) Copyright © 2011 Elsevier Ltd Terms and Conditions